Immune Design Corp  

(Public, NASDAQ:IMDZ)   Watch this stock  
Find more results for Christopher Kenney
-0.84 (-7.69%)
Feb 5 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 9.81 - 11.62
52 week 9.56 - 29.49
Open 10.79
Vol / Avg. 84,738.00/114,076.00
Mkt cap 187.63M
P/E     -
Div/yield     -
EPS -2.24
Shares 20.14M
Beta     -
Inst. own 100%
Mar 29, 2016
Q4 2015 Immune Design Corp Earnings Release (Estimated) Add to calendar
Feb 11, 2016
Immune Design Corp at Leerink Partners Global Healthcare Conference - 3:05PM EST - Add to calendar
Nov 18, 2015
Immune Design Corp at Jefferies Autumn Global Healthcare Conference
Nov 12, 2015
Q3 2015 Immune Design Corp Earnings Call - Webcast
Nov 12, 2015
Q3 2015 Immune Design Corp Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '15) 2014
Net profit margin -159.19% -530.87%
Operating margin -159.34% -464.45%
EBITD margin - -460.75%
Return on average assets -23.10% -62.46%
Return on average equity -24.33% -649.75%
Employees 33 -
CDP Score - -


1616 Eastlake Ave E Ste 310
SEATTLE, WA 98102-3788
United States - Map
+1-206-6820645 (Phone)
+1-206-6820648 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Immune Design Corp. is a clinical stage immunotherapy company with next-generation in vivo approaches designed to enable the body's immune system to fight disease. The Company is developing multiple product candidates from its two discovery platforms, ZVex and GLAAS, which it believes have the potential to treat a broad patient population either as individual therapies or in combination with other immuno-oncology mechanisms of action. The Company's primary product candidates, CMB305 and G100, utilize multiple immuno-oncology approaches and, it believes, address the shortcomings of existing therapies. The Company's immuno-oncology product candidates are being developed in two separate approaches. The Specific Antigen approach uses selected antigens that are also present in the patient's tumor. The Endogenous Antigen approach relies on endogenous tumor antigens released during tumor lysis by treatments, such as chemotherapy or local radiation.

Officers and directors

Edward E. Penhoet Ph.D. Independent Chairman of the Board
Bio & Compensation  - Reuters
Carlos V Paya President, Chief Executive Officer, Director
Age: 56
Bio & Compensation  - Reuters
Stephen R. Brady J.D. Principal Financial Officer, Principal Accounting Officer
Age: 45
Bio & Compensation  - Reuters
Jan Henrik Ter Meule M.D. Chief Scientific Officer
Age: 52
Bio & Compensation  - Reuters
Christopher Whitmore Vice President - Finance and Administration
Bio & Compensation  - Reuters
Wayne R. Gombotz Ph.D. Chief Development Officer
Age: 55
Bio & Compensation  - Reuters
Richard T. Kenney M.D. Chief Medical Officer
Age: 56
Bio & Compensation  - Reuters
Brian G. Atwood Independent Director
Age: 62
Bio & Compensation  - Reuters
David Baltimore Ph.D. Independent Director
Age: 77
Bio & Compensation  - Reuters
Franklin M. Berger Independent Director
Age: 65
Bio & Compensation  - Reuters